Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$23.41 USD
+0.47 (2.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $23.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Company Summary
Beam Therapeutics is a Massachusetts, U.S.-based biotechnology company committed to establishing a leading and fully integrated platform for precision genetic medicines through base editing. It has gene editing and delivery technologies in place to formulate medicines for treating serious diseases.
The company has been trading publicly since February 2020. Currently, it has no marketed drug in its portfolio. Beam Therapeutics is advancing base-editing technology across three disease-area portfolios — hematology, immunology/oncology and genetic diseases.
Beam Therapeutics has two early-stage clinical programs, BEAM-101 and BEAM-201, ...
Company Summary
Beam Therapeutics is a Massachusetts, U.S.-based biotechnology company committed to establishing a leading and fully integrated platform for precision genetic medicines through base editing. It has gene editing and delivery technologies in place to formulate medicines for treating serious diseases.
The company has been trading publicly since February 2020. Currently, it has no marketed drug in its portfolio. Beam Therapeutics is advancing base-editing technology across three disease-area portfolios — hematology, immunology/oncology and genetic diseases.
Beam Therapeutics has two early-stage clinical programs, BEAM-101 and BEAM-201, in its pipeline, being developed for hematological and immuno-oncology indications, respectively. The company has two other candidates — BEAM-301 and BEAM-302 — for genetic diseases, in its portfolio. It has initiated the dosing in the expansion cohort of its lead candidate, BEAM-101, in an early-stage study to treat patients with sickle cell disease (SCD).
Beam Therapeutics also initiated the phase I/II study of BEAM-201 by dosing the first patient with relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
In October 2023, Beam Therapeutics announced a strategic restructuring, including the reprioritization of its current portfolio of pipeline candidates, and business operations realignment. The restructuring and reprioritization efforts are expected to reduce the company’s operating expenses and enhance its cash position.
With no marketed product in its portfolio, the company generates only collaboration revenues. In 2023, Beam Therapeutics generated almost $377.7 million in collaboration revenues compared with $60.9 million in 2022.General Information
Beam Therapeutics Inc
238 Main Street
CAMBRIDGE, MA 02142
Phone: 857-327-8775
Fax: NA
Email: investors@beamtx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.13 |
Current Year EPS Consensus Estimate | -4.60 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 22.94 |
52 Week High | 49.50 |
52 Week Low | 16.95 |
Beta | 1.85 |
20 Day Moving Average | 791,021.94 |
Target Price Consensus | 50.36 |
4 Week | -5.13 |
12 Week | -11.36 |
YTD | -15.72 |
4 Week | -8.40 |
12 Week | -13.16 |
YTD | -29.48 |
Shares Outstanding (millions) | 82.42 |
Market Capitalization (millions) | 1,890.61 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -2.78% |
vs. Previous Quarter | 8.26% |
vs. Previous Year | -41.48% |
vs. Previous Quarter | 58.87% |
Price/Book | 2.21 |
Price/Cash Flow | NA |
Price / Sales | 5.36 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -16.22 |
3/31/24 | -15.46 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -10.65 |
3/31/24 | -9.86 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 5.81 |
3/31/24 | 5.99 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 5.81 |
3/31/24 | 5.99 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -40.56 |
3/31/24 | -37.33 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -40.56 |
3/31/24 | -37.33 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -40.16 |
3/31/24 | -36.95 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 10.38 |
3/31/24 | 11.10 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |